Group V phospholipase A2 mediates barrier disruption of human pulmonary endothelial cells caused by LPS in vitro

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 3, 2011, Pages 361-368

  Dudek, Steven M ^a   Muñoz, Nilda M ^a   Desai, Anjali ^a   Osan, Christopher M ^a   Meliton, Angelo Y ^a   Leff, Alan R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Actin; Acute lung injury; Cytoskeleton; Phospholipase A2; Vascular permeability

Indexed keywords

CADHERIN; F ACTIN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3G1; MUTANT PROTEIN; PHOSPHOLIPASE A2 GROUP V; UNCLASSIFIED DRUG;

ARTICLE; CELL PERMEABILIZATION; CELL SURFACE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LUNG ENDOTHELIUM; MONOLAYER CULTURE; PROTEIN CONTENT; PROTEIN EXPRESSION; STRESS FIBER; UPREGULATION; VASCULAR ENDOTHELIUM;

ACTINS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DEXTRANS; ENDOTHELIAL CELLS; GROUP V PHOSPHOLIPASES A2; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; MUTATION; RECOMBINANT PROTEINS; RNA, MESSENGER; TIME FACTORS;

EID: 79952213950     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0446OC     Document Type: Article

References (39)

1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-1693. (Pubitemid 41464707)
2. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
3. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009;37:1574-1579.
4. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest 2007;131:913-920. (Pubitemid 46446892)
5. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-1564. (Pubitemid 46670280)
6. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE. Endothelial pathomechanisms in acute lung injury. Vascul Pharmacol 2008;49:119-133.
7. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001;91:1487-1500. (Pubitemid 32900340)
8. 2. Cardiovasc Drugs Ther 2009;23:61-72.
9. 2 structure/function, mechanism, and signaling. J Lipid Res 2009;50:S237-S242.
10. 2: structural and functional changes. Am Rev Respir Dis 1991;143:1102-1109.
11. 2 in meconium-induced lung injury. J Perinatol 2008;28:S120-S122.
12. 2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005;33:772-779.
13. 2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 1995;269:L109-L118.
14. 2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. J Biol Chem 2006;281:6691-6698.
15. 2 to induce eicosanoid biosynthesis in neighboring inflammatory cells. J Biol Chem 2006;281:10935-10944.
16. Muñoz NM, Boetticher E, Sperling AI, Kim KP, Meliton AY, Zhu X, Lambertino A, Cho W, Leff AR. Quantitation of secretory group V phospholipase A(2) in human tissues by sandwich enzyme-linked immunosorbent assay. J Immunol Methods 2002;262:41-51.
17. 2). Hybridoma 2000;19:171-176.
18. 2 from epithelium induces beta 2-integrin-mediated adhesion and synthesis of leukotriene C4 in eosinophils. J Immunol 2006;177:574-582.
19. 2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice. Am J Physiol Lung Cell Mol Physiol 2009;296:L879-L887.
20. 2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem 2004;279:16488-16494.
21. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, Garcia JG. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004;279:24692-24700. (Pubitemid 38725337)
22. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689-701. (Pubitemid 32906197)
23. Camp SM, Bittman R, Chiang ET, Moreno-Vinasco L, Mirzapoiazova T, Sammani S, Lu X, Sun C, Harbeck M, Roe M, et al. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009;331:54-64.
24. Gong P, Angelini DJ, Yang S, Xia G, Cross AS, Mann D, Bannerman DD, Vogel SN, Goldblum SE. TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. J Biol Chem 2008;283:13437-13449.
25. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y, Natarajan V, Garcia JG. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007;19:1754-1764. (Pubitemid 46935431)
26. Schlegel N, Baumer Y, Drenckhahn D, Waschke J. Lipopolysaccharide-induced endothelial barrier breakdown is cyclic adenosine monophosphate dependent in vivo and in vitro. Crit Care Med 2009;37:1735-1743.
27. Wu S, Cioffi EA, Alvarez D, Sayner SL, Chen H, Cioffi DL, King J, Creighton JR, Townsley M, Goodman SR, et al. Essential role of a Ca2+-selective, store-operated current (ISOC) in endothelial cell permeability: determinants of the vascular leak site. Circ Res 2005;96:856-863. (Pubitemid 40604969)
28. Troyanovsky B, Alvarez DF, King JA, Schaphorst KL. Thrombin enhances the barrier function of rat microvascular endothelium in a PAR-1-dependent manner. Am J Physiol Lung Cell Mol Physiol 2008;294:L266-L275. (Pubitemid 351253363)
29. 2. J Biol Chem 1999;274:11881-11888.
30. 2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol 2007;179:4800-4807.
31. Vestweber D, Winderlich M, Cagna G, Nottebaum AF. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 2009;19:8-15.
32. Bannerman DD, Goldblum SE. Direct effects of endotoxin on the endothelium: barrier function and injury. Lab Invest 1999;79:1181-1199. (Pubitemid 29489444)
33. Bogatcheva NV, Zemskova MA, Kovalenkov Y, Poirier C, Verin AD. Molecular mechanisms mediating protective effect of cAMP on lipopolysaccharide (LPS)-induced human lung microvascular endothelial cells (HLMVEC) hyperpermeability. J Cell Physiol 2009;221:750-759.
34. 2 induce the expression of chemokines in microvascular endothelium. Biochem Biophys Res Commun 2003;300:731-737.
35. Bogatcheva NV, Sergeeva MG, Dudek SM, Verin AD. Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005;69:107-127. (Pubitemid 40731489)
36. 2. Annu Rev Biochem 2008;77:495-520.
37. 2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest 1996;97:2233-2241.
38. 2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem 2006;281:36420-36433.
39. Blum MS, Toninelli E, Anderson JM, Balda MS, Zhou J, O'Donnell L, Pardi R, Bender JR. Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Am J Physiol 1997;273:H286-H294.